Table 3.

Table reports the comparison of several features (hematological indication, safety, cost) in different hematological drugs that might have a role in the COVID-19. Abbreviations: MPN = chronic myeloproliferative neoplasms; MAS = macrophage activation syndrome; CML = chronic myeloid leukemia; ALL = acute lymphoblastic leukemia; GIST = stromal gastro-intestinal tumor; GVHD = graft-versus-host disease; LNH = non Hodgkin’s lymphoma; MM = multiple myeloma.

	Ruxolitinib	Imatinib	Dasatinib	Nilotinib	Bosutinib	Ibrutinib	Begelomab	IFN
Drug	os	os	os	os	os	os	IV	os
formulation
Clinical use in
GVHD	XX	X	X	X	–	XX	XX	–
Use in	MPNs	CML	CML	CML	CML	CLL	GVHD	CML
hematological	MAS	ALL	ALL	ALL		MCL		MPN
diseases		GIST						LNH
								MM
Infection rate	20 %	5%	11 %	17 %	4%	71 %	10 %	na
Estimated	++	+	+	+	+	+++	+++	+
costs